| 000 | 01672 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250514193005.0 | ||
| 264 | 0 | _c20041022 | |
| 008 | 200410s 0 0 eng d | ||
| 022 | _a0114-5916 | ||
| 024 | 7 |
_a10.2165/00002018-200427090-00005 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGavin, James R | |
| 245 | 0 | 0 |
_aMoxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies. _h[electronic resource] |
| 260 |
_bDrug safety _c2004 |
||
| 300 |
_a671-86 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAnti-Bacterial Agents _xadverse effects |
| 650 | 0 | 4 |
_aAza Compounds _xadverse effects |
| 650 | 0 | 4 |
_aBlood Glucose _xanalysis |
| 650 | 0 | 4 | _aClinical Trials, Phase II as Topic |
| 650 | 0 | 4 | _aClinical Trials, Phase III as Topic |
| 650 | 0 | 4 |
_aDiabetes Mellitus _xblood |
| 650 | 0 | 4 | _aFluoroquinolones |
| 650 | 0 | 4 |
_aGlucose _xmetabolism |
| 650 | 0 | 4 | _aHomeostasis |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHyperglycemia _xchemically induced |
| 650 | 0 | 4 |
_aHypoglycemia _xchemically induced |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMoxifloxacin |
| 650 | 0 | 4 | _aProduct Surveillance, Postmarketing |
| 650 | 0 | 4 |
_aQuinolines _xadverse effects |
| 650 | 0 | 4 | _aRats |
| 700 | 1 | _aKubin, Rolf | |
| 700 | 1 | _aChoudhri, Shurjeel | |
| 700 | 1 | _aKubitza, Dagmar | |
| 700 | 1 | _aHimmel, Hebert | |
| 700 | 1 | _aGross, Rainer | |
| 700 | 1 | _aMeyer, Jutta M | |
| 773 | 0 |
_tDrug safety _gvol. 27 _gno. 9 _gp. 671-86 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2165/00002018-200427090-00005 _zAvailable from publisher's website |
| 999 |
_c14934949 _d14934949 |
||